Coverage
Filings
Genmab A/S announced encouraging results from its Phase 1/2 RAINFOL-01 trial for rinatabart sesutecan (Rina-S), an investigational antibody-drug conjugate (ADC), in heavily pretreated patients with advanced endometrial cancer.
| Articles of association |
| 14 Jun 2010 |
| Genmab Presents Data from a Pivotal Trial of Zalutumumab Versus Best Supportive Care in Patients with Refractory Head and Neck Cancer | 7 Jun 2010 |
| Change in Constitution of the Board of Directors | 2 Jun 2010 |
| Grant of Warrants to Board Members, Management and Employees in Genmab | 2 Jun 2010 |
| Report Pursuant to Section 28a of the Danish Securities Trading Act | 2 Jun 2010 |